AMYT News and Press, Amryt Pharma plc From 09/23/22

Amryt Supports FH Awareness Day – September 24, 202 2 DUBLIN, Ireland, and Boston MA, September 2 3 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializi...

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's ( NASDAQ: AMYT ) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreo...

CHMP a dopts p ositive o pinion for Mycapssa ® for the t reatment of Acromegaly Positive o pinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 1 6 ...

Irish commercial-stage biopharma Amryt ( NASDAQ: AMYT ) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarke...

Amryt R eceives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN, Ireland, and Boston MA, S...

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, develop...

Krystal Bio (KRYS) has performed well in the last two months that I have had it. Its B-VEC looks highly approvable. With Amryt's CRL, the competitive gap has widened in favor of Krystal. Krystal Biotech ( KRYS ) is up hugely since I first covered it earlier this year...

Amryt Pharma plc (AMYT) Q2 2022 Earnings Conference Call August 04, 2022 08:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - Chief Executive Officer Rory Nealon - Chief Financial Officer and Chief Operating Officer Jord...

The following slide deck was published by Amryt Pharma plc in conjunction with their 2022 Q2 earnings call. For further details see: Amryt Pharma plc 2022 Q2 - Results - Earnings Call Presentation

Amryt Pharma press release ( NASDAQ: AMYT ): Q2 GAAP EPS of -$0.02 beats by $0.04 . Revenue of $68.54M (+9.2% Y/Y) beats by $4.28M . Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underwa...